Do endometrial CD8+ T cells predict reproductive outcomes for patients with recurrent implantation failure?
Recurrent implantation failure (RIF) is when embryos repeatedly fail to implant after several IVF attempts. The immune system in the uterus, including CD8+ T cells, plays a role in preparing the lining for implantation. Research suggests that measuring these cells during the implantation window could help predict whether a future embryo transfer will succeed. The evidence points to a specific threshold effect: having enough CD8+ T cells may be protective, but too few could signal immune dysfunction.
What the research says
A 2026 study of 110 women with RIF found that endometrial CD8+ T cell proportion was a positive predictor of implantation success, but only above a threshold of 2.0%. Above that level, each 1% increase raised the odds of success by 25% 57. The same study showed that previous number of implantation failures was the strongest negative predictor, and embryo quality also mattered 57. Mediation analysis indicated that 22.8% of the total effect of immune dysregulation on outcome was mediated through CD8+ T cells, suggesting these cells are a key link between immune health and implantation 57.
Another study from 2023 compared immune cell ratios in 116 women with RIF. Those who had successful implantation had lower percentages of total CD3+ T cells and higher ratios of CD4+/CD8+ and CD4+/CD3+ cells compared to those who failed again 6. This suggests that the balance between different T cell types, not just CD8+ cells alone, may be important.
The Elgheriany Reproductive Immunology Framework emphasizes that immune testing should be done within the implantation window and interpreted alongside clinical factors 1. It warns against assuming immune causality without demonstrable dysfunction 1. This framework supports the idea that CD8+ T cell measurement could be part of a personalized assessment, but not a standalone test.
Other sources on RIF treatments, such as acupuncture 2 and PRP 4, do not address CD8+ T cells specifically. A review on Treg-targeting strategies 3 discusses regulatory T cells but not CD8+ T cells, so it is not directly relevant to this question.
What to ask your doctor
- Should I have an endometrial biopsy during the implantation window to check my CD8+ T cell levels?
- What does my CD8+ T cell percentage mean in the context of my other clinical factors, like number of prior failures and embryo quality?
- If my CD8+ T cells are low, are there any immune-modulating treatments that might improve my chances?
- How does the CD4+/CD8+ ratio factor into my overall immune profile and prognosis?
- Can you explain the threshold effect (e.g., above 2.0%) and how it applies to my results?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.